Get the Stockscreener App
6.36
1.09%
-0.07
Fulcrum Therapeutics Inc stock is traded at $6.36, with a volume of 390.30K.
It is down -1.09% in the last 24 hours and down -7.56% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$6.43
Open:
$6.42
24h Volume:
390.30K
Relative Volume:
0.72
Market Cap:
$372.46M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.0253
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-6.88%
1M Performance:
-7.56%
6M Performance:
+50.35%
1Y Performance:
-2.00%
1-Day Range:
$6.33
$6.7401
1-Week Range:
$6.33
$6.965
52-Week Range:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.36 | 372.46M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Bank of America Corp DE Has $432,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Research Analysts Issue Forecasts for FULC FY2026 Earnings - Defense World
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Millennium Management LLC - Defense World
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Two Sigma Investments LP - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics Awards Major Stock Options Package: 70,000 Shares at $6.96 Exercise Price - Stock Titan
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - MSN
BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) shareholders are up 16% this past week, but still in the red over the last five years - simplywall.st
Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune
New Oral Sickle Cell Drug Shows Promise: Fulcrum to Reveal Phase 1 Trial Results at Global Medical Conferences - Stock Titan
Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus
Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus
FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | FULC Stock News - GuruFocus
Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan
Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World
Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World
Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada
Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com
Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus
Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com
Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada
Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World
Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq
Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com
Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus
Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus
FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus
Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World
Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fulcrum Therapeutics Inc Stock (FULC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sapir Alex | See Remarks |
Jul 03 '24 |
Option Exercise |
3.27 |
150,000 |
490,500 |
193,360 |
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):